Interestingly, they also found a cohort of meningiomas with a high CDKN2A mRNA expression (CDKN2Ahigh), which exhibited similarly aggressive outcomes to those with homozygous CDKN2A deletion and was enriched with transcriptomic pathways similar to those found in the CDKN2A homozygous loss group. This evidence concerns the gene CDKN2A and meningioma.